Beyond idiopathic pulmonary fibrosis: the world of progressive-fibrosing interstitial lung disease

In this issue, the European Respiratory Review publishes a series of articles on fibrosing interstitial lung diseases (ILDs) that present with a progressive phenotype. Progressive-fibrosing ILD (PF-ILD) is a terminology recently used to describe these patients. In addition to patients with idiopathic pulmonary fibrosis (IPF), there is a large and more diverse group of patients who develop PF-ILD. These patients are suffering from a disorder that shares a number of clinical features with IPF including: increasing respiratory symptoms; decline of the physiological functions; limited response to immunomodulatory therapy; premature mortality; and significantly impaired quality of life. These articles raise the awareness of these PF-ILDs and review our current understanding of their clinical behaviour and management. Olson et al. [1] report on the present status of epidemiology, with an overview on the incidence and prevalence of progressive-fibrosing lung disease. The presentation, diagnosis and clinical course of the spectrum of PF-ILD is well described by Cottin et al. [2], while the role of imaging is analysed in depth by Walsh et al. [3]. A detailed analysis of the key role, burden, management and definition of acute exacerbations in PF-ILD is provided by Kolb et al. [4]. Finally, Richeldi et al. [5] provide an interesting overview on the currently available management options in PF-ILD including possible future alternatives, while Swigris et al. [6] present a review on the evaluation and monitoring of the currently available patient-reported outcome instruments and Holtze et al. [7] discusses the problems related to the healthcare burden of these diseases.

Short abstract

Beyond IPF: the world of PF-ILD http://ow.ly/zZZ430mYeaE

In this issue, the European Respiratory Review publishes a series of articles on fibrosing interstitial lung diseases (ILDs) that present with a progressive phenotype. Progressive-fibrosing ILD (PF-ILD) is a terminology recently used to describe these patients. In addition to patients with idiopathic pulmonary fibrosis (IPF), there is a large and more diverse group of patients who develop PF-ILD. These patients are suffering from a disorder that shares a number of clinical features with IPF including: increasing respiratory symptoms; decline of the physiological functions; limited response to immunomodulatory therapy; premature mortality; and significantly impaired quality of life. These articles raise the awareness of these PF-ILDs and review our current understanding of their clinical behaviour and management. Olson et al. [1] report on the present status of epidemiology, with an overview on the incidence and prevalence of progressive-fibrosing lung disease. The presentation, diagnosis and clinical course of the spectrum of PF-ILD is well described by Cottin et al. [2], while the role of imaging is analysed in depth by Walsh et al. [3]. A detailed analysis of the key role, burden, management and definition of acute exacerbations in PF-ILD is provided by Kolb et al. [4]. Finally, Richeldi et al. [5] provide an interesting overview on the currently available management options in PF-ILD including possible future alternatives, while Swigris et al. [6] present a review on the evaluation and monitoring of the currently available patient-reported outcome instruments and Holtze et al. [7] discusses the problems related to the healthcare burden of these diseases.

Two further reviewes on ILD are published in this issue of the European Respiratory Review, in addition to those discussed above. The first in on a subject that is poorly investigated and understood; the mortality risk factors and mortality rates of these patients in intensive care units [8]. The second one is a systematic review on the benefits of chest magnetic resonance imaging in ILD [9].

As you may well understand, this set of contributions was provided by worldwide known authors who are leading experts in this field and who offer a comprehensive and rounded view on these conditions, which are closely related to IPF and that may present differences in their behaviour and the clinical approaches. I do believe that these overviews will represent for all of us an important point of reference for a pathology whose knowledge is rapidly evolving and calling for visions and integrated clinical approaches, such as those that are offered here.